@Article{or.2026.079988,
AUTHOR = {Shijia Lu, Yanmin Wang, Han Zhang, Mengjia Yan, Mengdan Sang, Jinle Wang, Huaying Du, Jinwen Sima, Yiran Zhen, Xue Yang, Yutong Zhang, Hongwei Zhou},
TITLE = {Targeting PCNA in Cancer: A Paradigm Shift from Static Inhibition to Dynamic Network Modulation},
JOURNAL = {Oncology Research},
VOLUME = {},
YEAR = {},
NUMBER = {},
PAGES = {{pages}},
URL = {http://www.techscience.com/or/online/detail/26826},
ISSN = {1555-3906},
ABSTRACT = {Proliferating Cell Nuclear Antigen (PCNA) is a core protein in DNA replication and repair. Its functional dysregulation drives tumorigenesis and therapeutic resistance, making it a critical anticancer target. However, the fundamental conflict between PCNA’s indispensable “guardian” function in normal cells and its hijacked “accomplice” role in cancer cells constitutes the central challenge for targeted intervention: how to eradicate tumors while avoiding severe toxicity to normal tissues. This review aims to systematically review the latest advances and translational dilemmas in the field of PCNA-targeted therapy. It outlines various intervention strategies, including small-molecule inhibitors, proteolysis-targeting chimeras, post-translational modification interference, and synthetic lethality approaches, analyzing their potential and limitations in preclinical research. The review focuses on dissecting key bottlenecks hindering clinical translation, such as the selectivity dilemma, delivery barriers, and resistance evolution. Concurrently, it critically examines how cross-disciplinary technologies—including artificial intelligence, spatiotemporal regulation, and synthetic biology—offer novel ideas to address these bottlenecks, while clarifying that most remain in early exploratory stages. By synthesizing progress, challenges, and future directions, this article provides a framework to inform the development of highly selective and translatable PCNA-based anticancer strategies.},
DOI = {10.32604/or.2026.079988}
}